title: [The technologies of genetic engineering in treatment of chronic lower limb ischemia].
abstract: The article contains experimental data on angiogenesis stimulated by plasmid containing the angiogenin gene. After the introduction of the gene construction, the number of capillars in the chorion-allantois membrane increases 2 to 3 times; in an ischemized limb of a rat it increases by 20 to 30%. Intramuscular administration of genetic engineering construction to patients with chronic lower limb ischemia improved the patients' condition, consisting in an increase in painless walking distance and ankle-brachial index, as well as in trophic defect healing and the betterment of muscular perfusion. Positive effects were noted after 2 to 4 weeks of treatment and remained during 6 to 24 months. There were no side-effects, except low grade fever during 1 to 2 days.
authors.forename: N P
authors.initials: NP
authors.lastname: Bochkov
authors.forename: B A
authors.initials: BA
authors.lastname: Konstantinov
authors.forename: A V
authors.initials: AV
authors.lastname: Gavrilenko
authors.forename: D A
authors.initials: DA
authors.lastname: Voronov
authors.forename: S V
authors.initials: SV
authors.lastname: Avdeeva
authors.forename: N V
authors.initials: NV
authors.lastname: Khaĭdarova
authors.forename: V Z
authors.initials: VZ
authors.lastname: Tarantul
authors.forename: E D
authors.initials: ED
authors.lastname: Sverdlov
authors.forename: B S
authors.initials: BS
authors.lastname: Naroditskiĭ
authors.forename: A L
authors.initials: AL
authors.lastname: Gintsburg
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000368:Aged; D000818:Animals; D002642:Chick Embryo; D002908:Chronic Disease; D003627:Data Interpretation, Statistical; D004195:Disease Models, Animal; D005260:Female; D005346:Fibroblast Growth Factors / Q000008:administration & dosage; D005500:Follow-Up Studies; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic; D010957:Plasmids / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D012259:Ribonuclease, Pancreatic / Q000235:genetics*; D013997:Time Factors; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage
chemical_list: D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; C046366:angiogenin; D012259:Ribonuclease, Pancreatic